For the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy.
Categories
Alkaloids
Antineoplastic Agents
Antineoplastic and Immunomodulating Agents
BCRP/ABCG2 Substrates
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 CYP3A4 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Drugs that are Mainly Renally Excreted
Enzyme Inhibitors
Immunosuppressive Agents
MATE 1 Inhibitors
MATE 1 Substrates
MATE 1 Substrates with a Narrow Therapeutic Index
MATE 2 Substrates
MATE 2 Substrates with a Narrow Therapeutic Index
MATE inhibitors
MATE substrates
Myelosuppressive Agents
Narrow Therapeutic Index Drugs
P-glycoprotein substrates
P-glycoprotein substrates with a Narrow Therapeutic Index
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682